Our earlier studies had shown that the two pseudomonads, Pseudomonas cepacia and Pseudomonas maltophilia, were organisms that were highly resisttant to most antibiotics. The present study was undertaken to determine the susceptibility of these bacteria to trimethoprim and the trimethoprim-sulfamethoxazole combination which has been used with apparent success in treating infections caused by these pseudomonads. All 51 strains of P. cepacia were inhibited by 2 ,gg or less of trimethoprim per ml, whereas all 45 of the P. maltophilia were resistant to greater than 32 gg/ml. When the P. maltophilia was tested against trimethoprim-sulfamethoxazole, two strains were resistant and one only moderately resistant, but all other strains were susceptible. All P. cepacia strains were also susceptible with an average zone of inhibition significantly larger than for P. maltophilia (P < 0.005). These in vitro studies support recent case study reports of successful therapy using the trimethoprim-sulfamethoxazole combination.
Both Pseudomonas cepacia and Pseudomonas maltophilia, two species of the genus Pseudomonas, are appearing more frequently in the medical literature as causative agents of human disease (1, la, 3, 5, 7, 9, 15, 17, 18, 22, 23) . These organisms are opportunistic pathogens which require unusually large inocula and/or impaired host defenses to initiate infection. Such findings prompted Moody et al. (14) to compare antibiotic susceptibilities of these species and three other less common pseudomonads to 12 antibiotics with those obtained for the most common species, P. aeruginosa (14) . The majority of P. cepacia were resistant to the 12 antibiotics studied and P. maltophilia was susceptible only to chloramphenicol, polymyxin B, and colistin (14) .
Trimethoprim is an antimicrobial compound which is effective against a number of pathogenic bacteria (1, 11) and its antibacterial action is potentiated by the sulfonamides, especially sulfamethoxazole (10) . Pseudomonas spp. have been reported to be resistant to this compound as well as to the combination of these drugs. However, clinical infections caused by both P. cepacia and P. maltophilia have been successfully treated with trimethoprim-sulfamethoxazole (la, 5, 9, 15, 18) . In the present study, minimum inhibitory concentrations (MIC) for trimethoprim were determined and disk susceptibility tests were performed with trimethoprim-sulfamethoxazole against strains of these two pseudomonads to establish their susceptibility to the new compound and the antibiotic combination.
MATERIALS AND METHODS Bacterial strains. Bacteria that were selected for testing were recovered from patients' specimens which were sent in for routine bacteriological examination at the Baltimore Cancer Research Center. Fifty-one test strains of P. cepacia and 45 of P. maltophilia were identified (19, 20) and supplied in pure cultures by Hazleton Laboratories, Reston, Va. Test strains were grown on 5% horse blood agar plates for 48 h at 30 C. Three isolated colonies of each strain were used to inoculate a tube of tryptose phosphate broth which was incubated for 18 h at 37 C.
Antibiotic disk susceptibility tests. Disk antimicrobial susceptibility testing was performed by a modification of the Kirby-Bauer method (3) in which: (i) the agar plates were flooded with a 103 organism/ml suspension diluted from the 18-h tryptose phosphate broth culture and the excess fluid was removed by suction; and (ii) the antibiotics were allowed to diffuse into the medium for 30 min before incubation. Single high potency disks of the following antibiotics were applied to the surface of a Mueller- 
RESULTS
Antibiotic susceptibility. Fifty-one strains of P. cepacia and 45 strains of P. maltophilia that were recovered from patients' specimens were selected for study. The majority of the strains colonized the upper respiratory tract; however, P. cepacia was the probable infective agent in two pneumonias. These strains were tested for susceptibility to 11 antibiotics and the results are shown in Table 2 . The 51 strains of P. cepacia were always resistant to cephalothin, ampicillin, streptomycin, tetracycline, polymixin B, and colistin, whereas P. maltophilia was usually resistant to the first four of these antimicrobial agents (93 to 98%), but rarely resistant to the latter two agents, i.e., 7 and 9%, respectively. Most strains of P. maltophilia were susceptible to chloramphenicol whereas only half of the P. cepacia strains were. Conversely, the latter strains were more susceptible to kanamycin (63%) and to carbenicillin (60%) than were the P. maltophilia strains (18 and 13%). The majority of strains of both species were resistant to gentamicin and neomycin. Trimethoprim MICs. The minimal concentrations of trimethoprim that were inhibitory for the 96 test strains are shown in cumulative percentage of distributions in Fig. 1 . Ninety percent of P. cepacia were inhibited (no visible growth after 72-h incubation) by 1 ug or less of trimethoprim per ml and the remaining 10% by 2,g/ml. Although nine strains were inhibited by 0.5 ,ug or less, 37 (72.5%) of the total P. cepacia strains were inhibited by 1 jig of trimethoprim per ml. It is apparent that P. cepacia clearly fell into a category of species that were susceptible to low concentrations of trimethoprim. In contrast, no strains of P. maltophilia were inhibited by 32 jig of trimethoprim per ml and are therefore resistant to this antimicrobial agent.
Susceptibility to trimethoprim-sulfamethoxazole. The zones of inhibition that were obtained when the 96 strains were tested with the combination of trimethoprim-sulfamethoxazole by the disk method are listed in Table 3 . Two strains of P. maltophilia had no zone of inhibition and they were also resistant to greater than 300 Ag of sulfamethoxazole per ml; another strain which was susceptible to the sulfonamide had a zone diameter of 15 (3, 6, 8, 17) , wounds (la, 7, 22) , and blood (1, 6, 7, 9, 18, 23). There is increasing evidence that these organisms are among those opportunistic pathogens that cause human infection when impaired host defense mechanisms exist or propitious circumstances favorable to continued exposure or large inocula occur (la, 3, 4, 9, 15) . Selection of the most effacacious antibiotic therapy for such infections clearly depends upon correct speciation of the organism and awareness that their antibiotic susceptibilities differ from the type species of this genus, P. aeruginosa. Results of in vitro antibiotic disk susceptibility tests indicate that P. cepacia is resistant to most of the antibiotics in general use for treatment of gram-negative bacillary infections, but is highly susceptible to trimethoprim; however, the development of resistance to trimethoprim during therapy presents an undesirable complication (1) . P. maltophilia, on the other hand, is resistant to trimethoprim but is usually susceptible to chloramphenicol, polymixin B, and colistin. Obviously, alternative therapeutic measures are desirable. The addition of a sulfonamide, such as sulfamethoxazole, to the trimethoprim is an alternative which not only prevents the development of trimethoprim-resistant strains, but also produces a potentiating effect against some microorganisms that are resistant to trimethoprim alone (10) . A synergistic effect has also been reported when these two drugs are combined with colistin (16) . Although all P. cepacia strains in this study were susceptible to trimethoprim as well as to the trimethoprim-sulfamethoxazole combination, the likelihood of trimethoprim-resistant strains developing in vivo would be decreased by the addition of the sulfa drug.
In contrast to P. cepacia, the P. maltophilia strains were resistant to trimethoprim, but all except two strains were susceptible to the combination. These two resistant strains were also resistant to the sulfonamide alone. This is in agreement with a previous study that reported that high resistance to each individual drug reduced, if not eliminated, the effectiveness of the combination (4). Although inhibition may be largely dependent on susceptibility of this organism to sulfamethoxazole, there were instances of minimal potentiation between the two drugs. Recent reports (la, 5, 15, 17) have demonstrated the efficacy of the trimethoprim-sulfamethoxazole combination in the therapy of P. cepacia and P. maltophilia infections. The in vitro results obtained in the present study support these findings and give evidence that further therapeutic trials should be undertaken.
